menu

Loading...

BMEA Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

1.420

Open

1.380

VWAP

1.37

Vol

878.26K

Mkt Cap

96.86M

Low

1.310

Amount

1.20M

EV/EBITDA(TTM)

--

Total Shares

70.70M

EV

50.22M

EV/OCF(TTM)

--

P/S(TTM)

--

Biomea Fusion, Inc. is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.

Show More

Events Timeline

(ET)

2026-01-12

08:40:00

Biomea Fusion Outlines Execution Priorities for 2026

2025-12-09 (ET)

2025-12-09

20:10:00

Biomea Fusion Releases KOL Interview Discussing icovamenib Use in Diabetes Patients

2025-12-05 (ET)

2025-12-05

07:10:00

Biomea Fusion Presents COVALENT-111 Study Results at WCIRDC

2025-11-05 (ET)

2025-11-05

07:37:05

Biomea Fusion to Present Two Posters on BMF-650 and Icovamenib

2025-11-04 (ET)

2025-11-04

16:56:43

Biomea Fusion announces Q3 earnings per share of 27 cents, below consensus estimate of 29 cents.

2025-10-27 (ET)

2025-10-27

08:13:13

Biomea Fusion reports first patient treated in Phase I trial of BMF-650

News

Globenewswire

2025-12-17Globenewswire

Biomea Fusion to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Globenewswire

2025-12-10Globenewswire

Biomea Fusion Unveils Clinical Results of Icovamenib, Advancing Diabetes Treatment

Newsfilter

2025-12-10Newsfilter

Biomea Fusion Unveils Clinical Results of Icovamenib, Advancing Diabetes Treatment

NASDAQ.COM

2025-12-05NASDAQ.COM

Biomea Fusion Highlights Long-lasting Advantages of Menin Inhibitor for Type 2 Diabetes

Globenewswire

2025-12-05Globenewswire

Biomea Fusion Presents COVALENT-111 Study Results, New Breakthrough in Diabetes Treatment

NASDAQ.COM

2025-12-03NASDAQ.COM

Biotech Stocks Rise After Hours: Clene Jumps Ahead of ALS Update; Werewolf, Biomea, and Dyne Also Gain

5 Analyst Rating

Wall Street analysts forecast BMEA stock price to rise

4 Buy

0 Hold

1 Sell

Moderate Buy

Current: 0.000

Low

4.00

Averages

7.75

High

12.00

Current: 0.000

Low

4.00

Averages

7.75

High

12.00

JPMorgan

Neutral -> Underweight

downgrade

AI Analysis

2025-11-15

Reason

JPMorgan

Price Target

AI Analysis

2025-11-15

downgrade

Neutral -> Underweight

Reason

JPMorgan downgraded Biomea Fusion to Underweight from Neutral without a price target. The firm views the recent phase 2 COVALENT II icovamenib data in type 2 diabetes as "interesting" but has concerns around the company's ability to fund the ongoing and planned studies. The funding may come with significant dilution over the long-term without a partnership, which is difficult to predict, the analyst tells investors in a research note.

Citi

Buy

downgrade

$7 -> $6

2025-11-10

Reason

Citi

Price Target

$7 -> $6

2025-11-10

downgrade

Buy

Reason

Citi lowered the firm's price target on Biomea Fusion to $6 from $7 and keeps a Buy rating on the shares following the Q3 report. The firm cites the company's higher spending and dilution from the recent public offering for the target drop.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BMEA

Unlock Now

Valuation Metrics

The current forward P/E ratio for Biomea Fusion Inc (BMEA.O) is -1.39, compared to its 5-year average forward P/E of -3.72. For a more detailed relative valuation and DCF analysis to assess Biomea Fusion Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-3.72

Current PE

-1.39

Overvalued PE

-0.87

Undervalued PE

-6.57

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-2.32

Current EV/EBITDA

-0.59

Overvalued EV/EBITDA

2.07

Undervalued EV/EBITDA

-6.71

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Whales Holding BMEA

Cormorant Asset Management, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Biomea Fusion Inc (BMEA) stock price today?

The current price of BMEA is 1.37 USD — it has increased 0

What is Biomea Fusion Inc (BMEA)'s business?

Biomea Fusion, Inc. is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.

What is the price predicton of BMEA Stock?

Wall Street analysts forecast BMEA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMEA is7.75 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Biomea Fusion Inc (BMEA)'s revenue for the last quarter?

Biomea Fusion Inc revenue for the last quarter amounts to -18.60M USD, decreased -45.36

What is Biomea Fusion Inc (BMEA)'s earnings per share (EPS) for the last quarter?

Biomea Fusion Inc. EPS for the last quarter amounts to -11550000.00 USD, decreased -54.53

How many employees does Biomea Fusion Inc (BMEA). have?

Biomea Fusion Inc (BMEA) has 106 emplpoyees as of March 03 2026.

What is Biomea Fusion Inc (BMEA) market cap?

Today BMEA has the market capitalization of 96.86M USD.